LATONYA SULTZER: Open Payments
NPI 1659744126 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$693 in 35 payments from 12 companies in 2025. Trend: 2023 $143 · 2024 $245 · 2025 $693
Food & beverage: $693
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $264 |
| Lilly USA, LLC | 9 | $140 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $68 |
| Astellas Pharma US Inc | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| ABBVIE INC. | 2 | $30 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| PFIZER INC. | 1 | $17 |
| RGH Enterprises LLC | 1 | $16 |
Products named: Ozempic, MOUNJARO, Kerendia, Wegovy, Veozah, TRELEGY ELLIPTA, AIRSUPRA, UBRELVY.
Industry payments across IN — which companies pay providers there.
